Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

被引：82

作者：

Cuzick, J. ^{[1
]}

Yang, Z. H. ^{[1
]}

Fisher, G. ^{[1
]}

Tikishvili, E. ^{[2
]}

Stone, S. ^{[2
]}

Lanchbury, J. S. ^{[2
]}

Camacho, N. ^{[3
]}

Merson, S. ^{[3
]}

Brewer, D. ^{[3
]}

Cooper, C. S. ^{[4
]}

Clark, J. ^{[4
]}

Berney, D. M. ^{[5
]}

Moller, H. ^{[6
]}

Scardino, P. ^{[7
]}

Sangale, Z. ^{[2
]}

机构：

[1] Queen Mary Univ London, Wolfson Inst Prevent Med, Ctr Canc Prevent, London EC1M 6BQ, England

[2] Myriad Genet Inc, Salt Lake City, UT 84108 USA

[3] Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England

[4] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England

[5] Queen Mary Univ London, Barts Canc Inst, Dept Mol Oncol, London EC1M 6BQ, England

[6] Kings Coll London, Thames Canc Registry, London SE1 3QD, England

[7] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA

来源：

BRITISH JOURNAL OF CANCER | 2013年 / 108卷 / 12期

关键词：

PTEN; localised prostate cancer; immunohistochemistry; FISH; prognostic factors; GENOMIC DELETION; BIOPSY COHORT; HIGH-RISK; EXPRESSION; PROGRESSION; SIGNATURE; ERG; RECURRENCE; FUSION; MARKER;

D O I：

10.1038/bjc.2013.248

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed by transurethral resection of the prostate. Methods: The PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH). The primary end point was death from prostate cancer. Results: The PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate analysis (hazard ratio (HR) = 3.51; 95% CI 2.60-4.73; P = 3.1 x 10(-14)). It was highly predictive of prostate cancer death in the 50% of patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR = 7.4; 95% CI 2.2-24.6; P = 0.012)), but had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (kappa=0.5). Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in the multivariate analyses. Conclusion: In low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.

引用

页码：2582 / 2589

页数：8

共 25 条

[1]

[Anonymous], MOD PATHOL, V24, P58

[2]

An Immunohistochemical Signature Comprising PTEN, MYC, and Ki67 Predicts Progression in Prostate Cancer Patients Receiving Adjuvant Docetaxel After Prostatectomy [J].

Antonarakis, Emmanuel S. ;

Keizman, Daniel ;

Zhang, Zhe ;

Gurel, Bora ;

Lotan, Tamara L. ;

Hicks, Jessica L. ;

Fedor, Helen L. ;

Carducci, Michael A. ;

De Marzo, Angelo M. ;

Eisenberger, Mario A. .

CANCER, 2012, 118 (24) :6063-6071

[3]

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Fisher, G. ;

Kovacs, G. ;

Flohr, P. ;

Berney, D. ;

Foster, C. S. ;

Fletcher, A. ;

Gerald, W. L. ;

Moller, H. ;

Reuter, V. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

ONCOGENE, 2008, 27 (03) :253-263

[4]

Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression end Akt activation [J].

Bedolla, Roble ;

Prihoda, Thomas J. ;

Kreisberg, Jeffrey I. ;

Malik, Shazli N. ;

Krishnegowda, Naveen K. ;

Troyer, Dean A. ;

Ghosh, Paramita M. .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3860-3867

[5]

Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study [J].

Berney, D. M. ;

Gopalan, A. ;

Kudahetti, S. ;

Fisher, G. ;

Ambroisine, L. ;

Foster, C. S. ;

Reuter, V. ;

Eastham, J. ;

Moller, H. ;

Kattan, M. W. ;

Gerald, W. ;

Cooper, C. ;

Scardino, P. ;

Cuzick, J. .

BRITISH JOURNAL OF CANCER, 2009, 100 (06) :888-893

[6]

Long-term outcome among men with conservatively treated localised prostate cancer [J].

Cuzick, J. ;

Fisher, G. ;

Kattan, M. W. ;

Berney, D. ;

Oliver, T. ;

Foster, C. S. ;

Moller, H. ;

Reuter, V. ;

Fearn, P. ;

Eastham, J. ;

Scardino, P. .

BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1186-1194

[7]

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort [J].

Cuzick, J. ;

Berney, D. M. ;

Fisher, G. ;

Mesher, D. ;

Moller, H. ;

Reid, J. E. ;

Perry, M. ;

Park, J. ;

Younus, A. ;

Gutin, A. ;

Foster, C. S. ;

Scardino, P. ;

Lanchbury, J. S. ;

Stone, S. .

BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1095-1099

[8]

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study [J].

Cuzick, Jack ;

Swanson, Gregory P. ;

Fisher, Gabrielle ;

Brothman, Arthur R. ;

Berney, Daniel M. ;

Reid, Julia E. ;

Mesher, David ;

Speights, V. O. ;

Stankiewicz, Elzbieta ;

Foster, Christopher S. ;

Moller, Henrik ;

Scardino, Peter ;

Warren, Jorja D. ;

Park, Jimmy ;

Younus, Adib ;

Flake, Dart D., II ;

Wagner, Susanne ;

Gutin, Alexander ;

Lanchbury, Jerry S. ;

Stone, Steven .

LANCET ONCOLOGY, 2011, 12 (03) :245-255

[9]

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression [J].

Ding, Zhihu ;

Wu, Chang-Jiun ;

Chu, Gerald C. ;

Xiao, Yonghong ;

Ho, Dennis ;

Zhang, Jingfang ;

Perry, Samuel R. ;

Labrot, Emma S. ;

Wu, Xiaoqiu ;

Lis, Rosina ;

Hoshida, Yujin ;

Hiller, David ;

Hu, Baoli ;

Jiang, Shan ;

Zheng, Hongwu ;

Stegh, Alexander H. ;

Scott, Kenneth L. ;

Signoretti, Sabina ;

Bardeesy, Nabeel ;

Wang, Y. Alan ;

Hill, David E. ;

Golub, Todd R. ;

Stampfer, Meir J. ;

Wong, Wing H. ;

Loda, Massimo ;

Mucci, Lorelei ;

Chin, Lynda ;

DePinho, Ronald A. .

NATURE, 2011, 470 (7333) :269-+

[10]

Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement [J].

Foster, C. S. ;

Dodson, A. R. ;

Ambroisine, L. ;

Fisher, G. ;

Moller, H. ;

Clark, J. ;

Attard, G. ;

De-Bono, J. ;

Scardino, P. ;

Reuter, V. E. ;

Cooper, C. S. ;

Berney, D. M. ;

Cuzick, J. .

BRITISH JOURNAL OF CANCER, 2009, 101 (07) :1137-1144

← 1 2 3 →